Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Jeff Sharman

Jeff Sharman

MD
Willamette Valley Cancer Institute and Research Center
The CRISTALLO study: obinutuzumab combined with venetoclax in previously untreated CLL 2:14
The CRISTALLO study: obinutuzumab combined with venetoclax in previously untreated CLL
Jeff Sharman • 9 Dec 2024
The Phase III BRUIN CLL-321 study: pirtobrutinib in CLL/SLL with prior covalent BTKi 2:35
The Phase III BRUIN CLL-321 study: pirtobrutinib in CLL/SLL with prior covalent BTKi
Jeff Sharman • 9 Dec 2024
Obinutuzumab +/- bendamustine debulking prior to venetoclax in CLL 2:36
Obinutuzumab +/- bendamustine debulking prior to venetoclax in CLL
Jeff Sharman • 7 Dec 2019
ELEVATE-TN: approval of acalabrutinib for adult CLL 3:16
ELEVATE-TN: approval of acalabrutinib for adult CLL
Jeff Sharman • 7 Dec 2019
The content of VJHemOnc is intended for healthcare professionals